c-Myc
Os inibidores de c-Myc têm como alvo a proteína c-Myc, um fator de transcrição que desempenha um papel crucial no crescimento celular, proliferação e apoptose. c-Myc regula a expressão de numerosos genes envolvidos no ciclo celular e é frequentemente superexpresso em vários tipos de câncer, levando a uma proliferação celular descontrolada e ao crescimento tumoral. Inibir o c-Myc pode interromper esses processos, induzindo a parada do ciclo celular e a apoptose em células cancerígenas. Os inibidores de c-Myc são ferramentas importantes na pesquisa do câncer e no desenvolvimento terapêutico. Na CymitQuimica, oferecemos uma ampla gama de inibidores de c-Myc de alta qualidade para apoiar sua pesquisa em oncologia, regulação do ciclo celular e controle transcricional.
Foram encontrados 69 produtos de "c-Myc"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EN4
CAS:<p>EN4 (EN4 MYC inhibitor) MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC.</p>Fórmula:C25H24N2O4Pureza:98.51%Cor e Forma:SolidPeso molecular:416.47PARL Protein, Human, Recombinant (Myc)
<p>Required for the control of apoptosis during postnatal growth.</p>Cor e Forma:Lyophilized PowderPeso molecular:37.8 kDa (predicted)ACOX1 Protein, Mouse, Recombinant (Myc)
<p>Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs.</p>Cor e Forma:Lyophilized PowderPeso molecular:76.2 kDa (predicted)2-5A-dependent Rnase Protein, Human, Recombinant (Myc)
<p>2-5A-dependent Rnase Protein, Human, Recombinant (Myc) is expressed in E.</p>Pureza:85% - 85%Cor e Forma:Lyophilized PowderPeso molecular:85.1 kDa (predicted)c-Myc inhibitor 9
CAS:<p>c-Myc inhibitor 9 (compound 332) with logEC50 ≥6, suppresses tumors in mice, useful for cancer research.</p>Fórmula:C27H31N5OSCor e Forma:SolidPeso molecular:473.63RK-9123016
CAS:<p>RK-9123016 is a SIRT2 inhibitor.</p>Fórmula:C16H18N6O3SPureza:99.65%Cor e Forma:SolidPeso molecular:374.42FUBP1-IN-2
CAS:<p>FUBP1-IN-2 hinders FUBP1, affects c-Myc and p21 expression, and depletes polyamines.</p>Fórmula:C26H26ClN3O4Cor e Forma:SolidPeso molecular:479.96KSI-3716
CAS:<p>KSI-3716 is a c-Myc inhibitor, a bladder chemotherapy agent that blocks the formation of complexes between c-MYC/MAX and target gene promoters.</p>Fórmula:C17H11BrCl2N2O2Pureza:98.94%Cor e Forma:SolidPeso molecular:426.09BI8622
CAS:<p>BI8622 is a HUWE1 antagonist that restores levels of RP2 mutants in retinal cell lines and inhibits cellular activation of NLRP3 and AIM2 inflammatory vesicles.</p>Fórmula:C25H26N6OPureza:98.28%Cor e Forma:SolidPeso molecular:426.51VPC-70619
CAS:<p>VPC-70619: Oral, selective N-Myc inhibitor; blocks cancer growth by hindering N-Myc-Max/DNA binding; well-absorbed.</p>Fórmula:C16H8ClF3N4OCor e Forma:SolidPeso molecular:364.71c-Myc inhibitor 8
CAS:<p>c-Myc inhibitor 8 suppresses cell growth in various cancers and is used in research.</p>Fórmula:C19H12BrClF3NO3S2Cor e Forma:SolidPeso molecular:538.79m-Se3
CAS:<p>m-Se3 is a potent, selective inhibitor of c-MYC transcription with demonstrated capability to inhibit tumor growth and exhibit anti-cancer activity [1].</p>Fórmula:C29H23IN2SePureza:98%Cor e Forma:SolidPeso molecular:605.37SYHA1815
CAS:<p>SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.</p>Fórmula:C27H26ClF4N5OCor e Forma:SolidPeso molecular:547.98KI-CDK9d-32
CAS:<p>KI-CDK9d-32 is a CDK9 PROTAC degrader with a DC50 of 0.89 nM. It facilitates the ubiquitination and degradation of CDK9, inhibits the MYC pathway, and disrupts nucleolar homeostasis. KI-CDK9d-32 demonstrates anticancer activity.</p>Fórmula:C39H45N9O4Cor e Forma:SolidPeso molecular:703.83c-Myc inhibitor 4
<p>Potent oral c-Myc inhibitor 4 reduces the proto-oncogene linked to tumor development.</p>Fórmula:C26H33FN6O3Cor e Forma:SolidPeso molecular:496.58BRD4 Inhibitor-40
CAS:<p>BRD4 Inhibitor-40 (Compound 23) functions as an inhibitor of BRD, effectively targeting BRD4-BD1, BRD4-BD2, BRD2-BD1, and BRD2-BD2, with IC50 values of 16.1, 142.18, 29.35, and 302.35 nM, respectively. It modulates the expression of c-Myc and p21, induces cell cycle arrest in the G1 phase, and inhibits Pkd1-deficient (PN) renal cystic epithelial cells. Additionally, it prevents renal cyst formation in both Madin-Darby canine kidney and embryonic kidney cyst models, and demonstrates renal cyst inhibition activity in mouse models.</p>Fórmula:C27H32N8OCor e Forma:SolidPeso molecular:484.596MY05
CAS:<p>MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).</p>Fórmula:C19H11ClN4OCor e Forma:SolidPeso molecular:346.77JY-3-094
CAS:<p>JY-3-094 is a selective Myc inhibitor that targets the hydrophobic domain of Myc and inhibits the formation of the Myc-Max heterodimer, with an IC50 of 33 μM, and can be used for cancer research.</p>Fórmula:C13H8N4O5Pureza:98.72%Cor e Forma:SolidPeso molecular:300.23β-catenin-IN-8
CAS:<p>β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.</p>Fórmula:C15H12ClN3O2SCor e Forma:SolidPeso molecular:333.79
